Back to search results

RAPID-CKD: Rapid Initiation of Four Guideline-Directed CKD Therapies

This study is testing if starting four kidney disease medicines (Finerenone, Semaglutide, Lotensin, Capoten/Enalapril) quickly and all at once is safe and effective for people with type 2 diabetes and chronic kidney disease. Researchers want to see if this rapid approach helps keep your kidney function stable, reduces protein in your urine (a sign of kidney damage), and if you can stay on all four medicines for 6 months. You might be able to join if you are 18-84 years old, have type 2 diabetes, and certain kidney function levels (eGFR 45 to ≤90 mL/min/1.73 m2 and UACR >200 mg/g). The study aims to enroll 64 participants, but its current status is unclear.

Study design
This is a pilot, open-label, randomized clinical trial with a planned enrollment of 64 participants. It compares a rapid treatment approach to usual care.
What's involved
You will have regular clinic visits and laboratory tests to monitor your kidney function, potassium levels, and how well you tolerate the treatment for 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants in both groups will be followed for 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07547878

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Not Yet Recruiting
PHASE4Ages 18–84InterventionalTreatment
Baylor Research Institute
~64 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:FinerenoneSemaglutideLotensinCapotenEnalaprilMonopril

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
On-study retention rate at 6 months
Measured over 6 months
+2 more outcomes measured

Conditions

Chronic Kidney Disease
Type 2 Diabetes

Explore related trials

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Texas1

Who to contact

Shahzeb Khan, MD
[email protected]
469-326-2636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients aged 18-84 years
eGFR 45 to ≤90 mL/min/1.73 m2
UACR \>200 mg/g
diagnosis of T2D
receiving ≤2 guideline-recommended drug classes irrespective of dose for ≥4 weeks prior to screening
eligible for all 4 drugs
systolic BP (SBP) \>90 mmHg
those willing to provide written informed consent and to adhere to study visits.

Exclusion

Type 1 diabetes
any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.)
history of kidney transplant
liver disease (i.e., aspartate transaminase or alanine transaminase \>5 times, or bilirubin \>3 times the upper limit of normal)
serum potassium \>5.5 mEq/L at baseline
known hypersensitivity to any study drug
life expectancy \<6 months
active malignancy or infection
brittle diabetes (defined as severe glycemic instability with hospitalization or emergency care for hypoglycemia or hyperglycemia within the past 6 months)
high-risk of hypoglycemia (Clarke or Gold score ≥4)
predicted 12-month risk of hypoglycemia related emergency visits or hospitalizations \>5% using the Kaiser Permanente hypoglycemia prediction score
high dose insulin use (\>1 unit/kg/day).
RASi: hyperkalemia or angioedema
SGLT2i: diabetic ketoacidosis, type 1 diabetes, recurrent genitourinary infections
ns-MRA: hyperkalemia
GLP1-RA: personal or family history of medullary thyroid carcinoma, known gastroparesis, or pancreatitis.

What this trial measures

  • On-study retention rate at 6 months6 months

    Proportion of participants who remain on all four guideline-directed CKD therapies at maximally tolerated doses without permanent discontinuation

  • Sustained decline in eGFR ≥30%6 months

    Proportion of participants with sustained decline in estimated glomerular filtration rate (eGFR; two consecutive readings ≥2 weeks apart)

  • Change in UACR6 months

    Relative change in log-transformed urine albumin-to-creatinine ratio (UACR) from baseline to 6 months